ResMed Inc. RMD
222.00
0.11
0.05%
as of 25 Sep
- Market cap
- $31.9B
- P/E
- 21.3×
Follow RMD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
ResMed Inc. (RMD) EBITDA
ResMed Inc.'s EBITDA for fiscal 2026 was $2.1B, up 10.9% from $1.9B in fiscal 2025. Over the past ten years it has ranged from $482.3M (fiscal 2015) to $2.1B (fiscal 2026) — the current reading is the highest in ten years. EBITDA has risen for 11 consecutive fiscal years. ResMed Inc. ranks 6th of 51 Medical Instruments & Supplies companies by EBITDA.
EBITDA, annual
Annual
| Period | EBITDA | Change |
|---|---|---|
| FY2026 | $2.1B | 10.91% |
| FY2025 | $1.9B | 25.07% |
| FY2024 | $1.5B | 15.55% |
| FY2023 | $1.3B | 11.33% |
| FY2022 | $1.2B | 9.03% |
| FY2021 | $1.1B | 10.51% |
| FY2020 | $991.0M | 35.75% |
| FY2019 | $730.1M | 10.32% |
| FY2018 | $661.8M | 23.02% |
| FY2017 | $538.0M | 4.30% |
Quarterly
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $503.8M | (11.43%) |
| Mar 2026 | $568.8M | 2.68% |
| Dec 2025 | $554.0M | 9.87% |
| Sep 2025 | $504.2M | (4.66%) |
| 42 more quarters | Free account |
Against its own ten years
Low $482.3M
High $2.1B
Ten-year median
$1.0B
Current reading's percentile
100
EBITDA against peers
| Company | EBITDA |
|---|---|
| MDLN Medline Inc. compare | $10.0B |
| BDX Becton, Dickinson and Company compare | $4.8B |
| ALC Alcon compare | $2.7B |
| SOLV Solventum Corporation compare | $2.6B |
| RMD ResMed Inc. | $2.1B |
| BAX Baxter International Inc. compare | $1.5B |
| COO The Cooper Companies, Inc. compare | $928.2M |
| WST West Pharmaceutical Services, Inc. compare | $861.8M |
| RGEN Repligen Corporation compare | $161.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on RMD
- Revenue
- Net income
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement